Grifols, S.A.는 주당 0.18의 연간 배당금을 지급하며, 수익률은 0.00%입니다. 배당금은 연간에 지급되며, 마지막 배당금 지급일은 Aug 12, 2025였습니다.
배당수익률
연간 배당금
배당금 지급일 전일
0.00%
$0.18
Aug 12, 2025
지급 빈도
지급 비율
연간
0.00%
배당금 이력
배당금 지급일 전일
현금 금액
기록 일자
지급일
Aug 12, 2025
$0.1758
Aug 12, 2025
Aug 20, 2025
Aug 12, 2025
$0.1734
Aug 12, 2025
Aug 20, 2025
Jun 3, 2021
$0.4566
Jun 4, 2021
Jun 14, 2021
Oct 30, 2020
$0.2014
Nov 2, 2020
Nov 9, 2020
Dec 2, 2019
$0.2219
Dec 3, 2019
Dec 11, 2019
Jun 7, 2019
$0.1756
Jun 10, 2019
Jun 18, 2019
배당금 차트
GRFS 배당금
GRFS 배당금 성장률(년간 비교)
Follow-Up Questions
Grifols, S.A.의 현재 배당금과 연간 배당금은 얼마인가요?
Grifols, S.A.이 현재 지급하는 배당금은 $0.1758입니다. Grifols, S.A.의 연간 배당금은 $0.18입니다.
Grifols, S.A.의 배당 성향은 얼마인가요?
Grifols, S.A.의 배당 성향은 0.00%입니다.
GRFS의 배당락일은 언제인가요?
Grifols, S.A.의 배당락일은 Aug 12, 2025입니다.
Grifols, S.A.은 얼마나 자주 배당금을 지급하나요?
분기별. Grifols, S.A.이 마지막으로 배당금을 지급한 날짜는 Aug 20, 2025입니다.
주요 통계
이전 종가
$8.05
시가
$8.02
일일 범위
$7.94 - $8.06
52주 범위
$6.19 - $11.14
거래량
431.1K
평균 거래량
583.4K
EPS(TTM)
0.62
배당수익률
--
시가총액
$2.0B
Grifols, S.A.란 무엇인가요?
Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.